Healthcare ❯ Pharmaceuticals ❯ Drug Approval

FDA Regulations

Clinical Trials Chronic Kidney Disease Off-Label Use Addyi Hypertension Treatments Clinical Research Wegovy Leqembi Semaglutide Eli Lilly Medication Access

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

The $1.5 billion pre‑launch cache signals a bid to avoid past GLP‑1 supply gaps ahead of an expected spring FDA ruling on the once‑daily pill.

Shareholder Law Firms Expand Probes of Corcept After FDA CRL for Relacorilant

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65